Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Plos One|September 4, 2009
A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signalingRichard A Klinghoffer, Jason Frazier, James Annis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA SequencingBrian S Roberts, Andrew A Hardigan, Dianna E Moore, et al.
BMC Cancer|April 18, 2017
Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patternsMarie K Kirby, Ryne C Ramaker, Brian S Roberts, et al.
Breast Cancer Research and Treatment|June 16, 2014
Recurrent read-through fusion transcripts in breast cancerKatherine E Varley, Jason Gertz, Brian S Roberts, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
The colorectal microRNAomeJordan M Cummins, Yiping He, Rebecca J Leary, et al.
Science Signaling|May 28, 2009
Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signalingRichard G James, Travis L Biechele, William H Conrad, et al.
Science Signaling|November 13, 2008
New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screeningMichael B Major, Brian S Roberts, Jason D Berndt, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2016
USP6 oncogene promotes Wnt signaling by deubiquitylating FrizzledsBabita Madan, Matthew P Walker, Robert Young, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
<i>MAPT</i> expression is mediated by long-range interactions with <i>cis</i>-regulatory elementsBrianne B Rogers, Ashlyn G Anderson, Shelby N Lauzon, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Pageof 3